OptimizeRx (OPRX) to Release Quarterly Earnings on Wednesday

OptimizeRx (NASDAQ:OPRX - Get Free Report) will issue its quarterly earnings data after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of $0.06 per share for the quarter. OptimizeRx has set its FY 2024 guidance at EPS.Investors that are interested in participating in the company's conference call can do so using this link.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.11. OptimizeRx had a negative return on equity of 5.97% and a negative net margin of 21.53%. The company had revenue of $18.81 million for the quarter, compared to the consensus estimate of $20.47 million. On average, analysts expect OptimizeRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OptimizeRx Stock Up 20.5 %

NASDAQ OPRX traded up $1.05 during trading hours on Wednesday, reaching $6.16. 217,655 shares of the company traded hands, compared to its average volume of 127,427. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $112.86 million, a PE ratio of -5.86 and a beta of 1.32. OptimizeRx has a 12 month low of $5.04 and a 12 month high of $16.65. The company has a 50 day moving average of $6.98 and a two-hundred day moving average of $9.20.

Analyst Ratings Changes

OPRX has been the topic of several analyst reports. B. Riley started coverage on shares of OptimizeRx in a research note on Thursday, July 25th. They issued a "buy" rating and a $18.50 price target on the stock. Barclays decreased their price target on OptimizeRx from $15.00 to $11.00 and set an "equal weight" rating for the company in a research report on Monday, August 12th. Finally, Royal Bank of Canada reduced their price target on shares of OptimizeRx from $17.00 to $14.00 and set an "outperform" rating for the company in a research report on Friday, August 16th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $14.50.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.